Incidence, risk factors for and prognostic role of thromboembolic events (TEEs) amongst patients with metastatic pancreatic adenocarcinoma (PAAD): a retrospective, single-center analysis

被引:0
作者
Santos, Cicero Gonzaga [1 ]
Maia Jr, Francisco de Assis [1 ]
Camandaroba, Marcos Pedro Guedes [1 ]
de Jesus, Victor Hugo Fonseca [2 ,3 ,4 ]
机构
[1] AC Camargo Canc Ctr, Dept Med Oncol, BR-01509010 Sao Paulo, SP, Brazil
[2] Ctr Pesquisas Oncol CEPON, Dept Med Oncol, BR-88034000 Florianopolis, SC, Brazil
[3] Oncoclinicas, Dept Gastrointestinal Med Oncol, BR-88015020 Florianopolis, Brazil
[4] A C Camargo Canc Ctr, Postgrad Sch, BR-01509010 Sao Paulo, SP, Brazil
关键词
thromboembolic; thrombosis; embolism; metastatic; pancreatic; cancer; PATIENTS RECEIVING CHEMOTHERAPY; VENOUS THROMBOEMBOLISM; CANCER; THROMBOSIS; THROMBOPROPHYLAXIS; PROJECTIONS; GEMCITABINE; BIOMARKER; HEPARIN; CA-19-9;
D O I
10.3332/ecancer.2024.1738
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Thromboembolic events (TEEs) are frequent among patients with pancreatic adenocarcinoma (PAAD). We set out to estimate the incidence and establish predictive risk factors for TEE and estimate the impact of TEEs on the overall survival (OS) of patients with metastatic PAAD. Methods: This is a retrospective, single-center study. We included patients with a pathologically confirmed diagnosis of PAAD with distant metastases treated at AC Camargo Cancer Center from 2016 to 2021. We used the competitive risk survival models to estimate the cumulative incidence of TEE. Risk factors for the development of TEEs were evaluated using the competitive risk and logistic regression models. The impact of TEEs on OS was assessed using both landmark and time-dependent covariate Cox survival analyses. Results: The study population consists of 199 patients. The cumulative incidence of TEEs in 1, 6 and 24 months were 10.1%, 19.3% and 30.2%, respectively. Log10(CA 10 (CA 19-9) was the only factor independently associated with increased risk of TEEs in the logistic regression (Odds ratio = 1.03; 95% confidence interval (95%CI), 1.00-1.06; p = 0.030) and competitive risk survival (Subdistribution hazard ratio = 1.14; 95%CI, 1.02-1.27; p = 0.019) models. In the landmark analysis, early TEEs (within 1 month of diagnosis) were not associated with inferior OS. In the time-dependent covariate Cox proportional hazard model, TEEs were not found to be statistically associated with inferior OS, although there was a trend towards it (Hazard ratio = 1.59; 95%CI, 0.99-2.54; p = 0.051). Conclusion: TEEs occur in a large fraction of patients with metastatic PAAD. Statistical models with higher predictive performance are currently needed. For the time being, consideration for prophylactic anticoagulation should be done on an individual basis.
引用
收藏
页数:18
相关论文
共 44 条
[1]   Pancreatic Carcinoma, Thrombosis and Mean Platelet Volume: Single Center Experience from the Southeast Region of Turkey [J].
Afsar, Cigdem Usul ;
Gunaldi, Meral ;
Kum, Pinar ;
Sahin, Berksoy ;
Erkisi, Melek ;
Kara, Ismail Oguz ;
Paydas, Semra ;
Duman, Berna Bozkurt ;
Ercolak, Vehbi ;
Karaca, Feryal ;
Uyeturk, Ummugul ;
Guner, Sebnem Izmir .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (21) :9143-9146
[2]   Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer [J].
Agnelli, Giancarlo ;
George, Daniel J. ;
Kakkar, Ajay K. ;
Fisher, William ;
Lassen, Michael R. ;
Mismetti, Patrick ;
Mouret, Patrick ;
Chaudhari, Umesh ;
Lawson, Francesca ;
Turpie, Alexander G. G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (07) :601-609
[3]   Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study [J].
Agnelli, Giancarlo ;
Gussoni, Gualberto ;
Bianchini, Carlo ;
Verso, Melina ;
Mandala, Mario ;
Cavanna, Luigi ;
Barni, Sandra ;
Labianca, Roberto ;
Buzzi, Franco ;
Scambia, Giovanni ;
Passalacqua, Rodolfo ;
Ricci, Sergio ;
Gasparini, Giampietro ;
Lorusso, Vito ;
Bonizzoni, Erminio ;
Tonato, Maurizio .
LANCET ONCOLOGY, 2009, 10 (10) :943-949
[4]  
AMBRUS JL, 1975, J MED, V6, P61
[5]  
BARBOSA Isabelle Ribeiro, 2018, Arq. Gastroenterol., V55, P230, DOI [10.1590/s0004-2803.201800000-59, 10.1590/s0004-2803.201800000-59, 10.1590/S0004-2803.201800000-59]
[6]   High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study [J].
Berger, Anne Katrin ;
Singh, Hans Martin ;
Werft, Wiebke ;
Muckenhuber, Alexander ;
Sprick, Martin R. ;
Trumpp, Andreas ;
Weichert, Wilko ;
Jaeger, Dirk ;
Springfeld, Christoph .
PANCREATOLOGY, 2017, 17 (04) :629-634
[7]   Risks and impacts of thromboembolism in patients with pancreatic cancer [J].
Chan, Landon L. ;
Lam, Ky ;
Lam, Daisy C. M. ;
Lau, Ym ;
Li, L. ;
Ng, Kelvin K. C. ;
Tang, Raymond S. Y. ;
Chan, Stephen L. .
HONG KONG MEDICAL JOURNAL, 2023, 29 (05) :396-403
[8]  
DOUGLASS HO, 1990, INT J PANCREATOL, V7, P135
[9]   Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline [J].
Falanga, A. ;
Ay, C. ;
Di Nisio, M. ;
Gerotziafas, G. ;
Jara-Palomares, L. ;
Langer, F. ;
Lecumberri, R. ;
Mandala, M. ;
Maraveyas, A. ;
Pabinger, I. ;
Sinn, M. ;
Syrigos, K. ;
Young, A. ;
Jordan, K. .
ANNALS OF ONCOLOGY, 2023, 34 (05) :452-467
[10]   Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes [J].
Frere, Corinne ;
Bournet, Barbara ;
Gourgou, Sophie ;
Fraisse, Julien ;
Canivet, Cindy ;
Connors, Jean M. ;
Buscail, Louis ;
Farge, Dominique .
GASTROENTEROLOGY, 2020, 158 (05) :1346-+